Kristina M. Holton
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kristina M. Holton has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Aravind Subramanian
Broad Institute of MIT and Harvard
1 shared publicationAustin J. Brockmeier
Center for Bioinformatics and Computational Biology, University of Delaware, Newark, DE, 19716, USA
1 shared publication- Kaden L. Nystuen
Department of Chemical Engineering, University of Massachusetts Amherst, Amherst, MA 01003, USA
1 shared publication - Lee L. Rubin
Department of Stem Cell and Regenerative Biology, Harvard University
1 shared publication - Margaret M. DeAngelis
Department of Ophthalmology, Ross Eye Institute, Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Buffalo, USA
1 shared publication - Mei-Hua Hall
McLean Hospital MA USA
1 shared publication
Latest Publications
- Open Access
- 4 February 2026
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 19, 1695359
An induced pluripotent stem cell-based chemical genetic approach for studying spinal muscular atrophy
Introduction: Spinal muscular atrophy (SMA) is a genetic disease characterized by degeneration of spinal cord motor neurons and neuromuscular junctions. Despite recent developments in therapies for SMA, treatment efficacy largely relies on the administration of drugs early in disease progression and is impacted by underlying patient genetics. Drug discovery for other diseases of the central nervous system (CNS) has also been hindered by heterogeneity in patient genetics and clinical presentations, as well as the need for early intervention. Methods: To address these hurdles, we utilized a chemical-genetic-based screening approach to adapt the Connectivity Map (CMAP)/L1000 platform to study SMA. To do this, we differentiated moderate and severe SMA patient-specific induced pluripotent stem cells into neuronal cells utilizing a forward programming differentiation protocol, exposed each to 360 neuroactive or CNS disease-related compounds, and interrogated resulting changes in expression of >400 neural genes in a platform we term CMAP neuro . Results: In doing so, we generated 4,559 transcriptional profiles identifying stimuli that modulate gene expression differences across SMA neurons. Finally, we make these data queryable, allowing the research community to (1) identify CNS disease-related perturbagens that mimic or reverse differentially expressed genes, or (2) explore the transcriptional response of a given perturbation in diverse SMA neuronal cells. Discussion: Taken together, CMAP neuro represents a novel tool to identify candidate stimuli for follow-up investigation into the biology of SMA and related disorders.
- 4 February 2026
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 19, 1695359
Open AccessAn induced pluripotent stem cell-based chemical genetic approach for studying spinal muscular atrophy
Introduction: Spinal muscular atrophy (SMA) is a genetic disease characterized by degeneration of spinal cord motor neurons and neuromuscular junctions. Despite recent developments in therapies for SMA, treatment efficacy largely relies on the administration of drugs early in disease progression and is impacted by underlying patient genetics. Drug discovery for other diseases of the central nervous system (CNS) has also been hindered by heterogeneity in patient genetics and clinical presentations, as well as the need for early intervention. Methods: To address these hurdles, we utilized a chemical-genetic-based screening approach to adapt the Connectivity Map (CMAP)/L1000 platform to study SMA. To do this, we differentiated moderate and severe SMA patient-specific induced pluripotent stem cells into neuronal cells utilizing a forward programming differentiation protocol, exposed each to 360 neuroactive or CNS disease-related compounds, and interrogated resulting changes in expression of >400 neural genes in a platform we term CMAP neuro . Results: In doing so, we generated 4,559 transcriptional profiles identifying stimuli that modulate gene expression differences across SMA neurons. Finally, we make these data queryable, allowing the research community to (1) identify CNS disease-related perturbagens that mimic or reverse differentially expressed genes, or (2) explore the transcriptional response of a given perturbation in diverse SMA neuronal cells. Discussion: Taken together, CMAP neuro represents a novel tool to identify candidate stimuli for follow-up investigation into the biology of SMA and related disorders.
- 14 August 2025
- Published by Springer Nature in Neuroinformatics
- Vol. 23 (3) , 43
Latent Growth Models of Longitudinal Changes in Functional Connectivity during Early Stage Psychosis
Resting state functional magnetic resonance imaging (fMRI) is a useful technique to characterize functional connectivity patterns between regions of the brain, based on the Fisher-transformed Pearson correlations in the BOLD signal. Pinpointing how connectivity patterns change in neuropathies like early-stage psychosis (ESP) can help understand the disorders and track progression. Using study data from 21 ESP subjects with complete data for three consecutive scans, we examined connectivity changes throughout the whole brain with a region of interest (ROI) to ROI-based approach for ROI defined by the Harvard-Oxford cortical and subcortical atlases, supplemented by the AAL atlas for the cerebellum, and by networks defined by the CONN toolbox independent component analysis of the Human Connectome Project. We applied latent growth modelling, which is a type of structural equation modelling, to these connectivity measurements across baseline and follow-up visits. The models use age, community functioning, and negative symptoms at baselines as the covariates for subject-specific slope and intercept of the longitudinal measurements. After stringent thresholding cutoffs of root mean square error of approximation, standardized root mean square residual, comparative fit index, and Benjamini-Hochberg corrected p-value, we found a subset of connectivity measurements with significant longitudinal slopes (N = 18 atlas, N = 6 network), and used the subject's slope estimates to stratify these subjects into three clusters based on how the ROI-to-ROI correlations of functional connectivity change over time. The connections with significant slopes include atlas level regions like the temporal lobe, fronto-parietal lobe, and cerebellum, and network level patterns like the DMN, FPN, and Salience Networks. The structural equation modelling approach identifies ROIs whose functional connectivity changes over time, indicating the ROIs most dynamic during ESP. This highlights the utility of latent growth models for the analysis of longitudinal functional connectivity measures across the whole brain with relatively small sample sizes.
- 14 August 2025
- Published by Springer Nature in Neuroinformatics
- Vol. 23 (3) , 43
Latent Growth Models of Longitudinal Changes in Functional Connectivity during Early Stage Psychosis
Resting state functional magnetic resonance imaging (fMRI) is a useful technique to characterize functional connectivity patterns between regions of the brain, based on the Fisher-transformed Pearson correlations in the BOLD signal. Pinpointing how connectivity patterns change in neuropathies like early-stage psychosis (ESP) can help understand the disorders and track progression. Using study data from 21 ESP subjects with complete data for three consecutive scans, we examined connectivity changes throughout the whole brain with a region of interest (ROI) to ROI-based approach for ROI defined by the Harvard-Oxford cortical and subcortical atlases, supplemented by the AAL atlas for the cerebellum, and by networks defined by the CONN toolbox independent component analysis of the Human Connectome Project. We applied latent growth modelling, which is a type of structural equation modelling, to these connectivity measurements across baseline and follow-up visits. The models use age, community functioning, and negative symptoms at baselines as the covariates for subject-specific slope and intercept of the longitudinal measurements. After stringent thresholding cutoffs of root mean square error of approximation, standardized root mean square residual, comparative fit index, and Benjamini-Hochberg corrected p-value, we found a subset of connectivity measurements with significant longitudinal slopes (N = 18 atlas, N = 6 network), and used the subject's slope estimates to stratify these subjects into three clusters based on how the ROI-to-ROI correlations of functional connectivity change over time. The connections with significant slopes include atlas level regions like the temporal lobe, fronto-parietal lobe, and cerebellum, and network level patterns like the DMN, FPN, and Salience Networks. The structural equation modelling approach identifies ROIs whose functional connectivity changes over time, indicating the ROIs most dynamic during ESP. This highlights the utility of latent growth models for the analysis of longitudinal functional connectivity measures across the whole brain with relatively small sample sizes.
- Open Access
- 1 January 2024
- Published by MDPI AG in Bioengineering
- Vol. 11 (1) , 45
Alzheimer’s Disease: Models and Molecular Mechanisms Informing Disease and Treatments
Alzheimer’s Disease (AD) is a complex neurodegenerative disease resulting in progressive loss of memory, language and motor abilities caused by cortical and hippocampal degeneration. This review captures the landscape of understanding of AD pathology, diagnostics, and current therapies. Two major mechanisms direct AD pathology: (1) accumulation of amyloid β (Aβ) plaque and (2) tau-derived neurofibrillary tangles (NFT). The most common variants in the Aβ pathway in APP, PSEN1, and PSEN2 are largely responsible for early-onset AD (EOAD), while MAPT, APOE, TREM2 and ABCA7 have a modifying effect on late-onset AD (LOAD). More recent studies implicate chaperone proteins and Aβ degrading proteins in AD. Several tests, such as cognitive function, brain imaging, and cerebral spinal fluid (CSF) and blood tests, are used for AD diagnosis. Additionally, several biomarkers seem to have a unique AD specific combination of expression and could potentially be used in improved, less invasive diagnostics. In addition to genetic perturbations, environmental influences, such as altered gut microbiome signatures, affect AD. Effective AD treatments have been challenging to develop. Currently, there are several FDA approved drugs (cholinesterase inhibitors, Aß-targeting antibodies and an NMDA antagonist) that could mitigate AD rate of decline and symptoms of distress.
- 1 January 2024
- Published by MDPI AG in Bioengineering
- Vol. 11 (1) , 45
Open AccessAlzheimer’s Disease: Models and Molecular Mechanisms Informing Disease and Treatments
Alzheimer’s Disease (AD) is a complex neurodegenerative disease resulting in progressive loss of memory, language and motor abilities caused by cortical and hippocampal degeneration. This review captures the landscape of understanding of AD pathology, diagnostics, and current therapies. Two major mechanisms direct AD pathology: (1) accumulation of amyloid β (Aβ) plaque and (2) tau-derived neurofibrillary tangles (NFT). The most common variants in the Aβ pathway in APP, PSEN1, and PSEN2 are largely responsible for early-onset AD (EOAD), while MAPT, APOE, TREM2 and ABCA7 have a modifying effect on late-onset AD (LOAD). More recent studies implicate chaperone proteins and Aβ degrading proteins in AD. Several tests, such as cognitive function, brain imaging, and cerebral spinal fluid (CSF) and blood tests, are used for AD diagnosis. Additionally, several biomarkers seem to have a unique AD specific combination of expression and could potentially be used in improved, less invasive diagnostics. In addition to genetic perturbations, environmental influences, such as altered gut microbiome signatures, affect AD. Effective AD treatments have been challenging to develop. Currently, there are several FDA approved drugs (cholinesterase inhibitors, Aß-targeting antibodies and an NMDA antagonist) that could mitigate AD rate of decline and symptoms of distress.